September 1, 2021

## Strategy Update on Alzheimer's Disease & NeuroRestore



## Today's presenters

		EXPERIENCES
<b>Maria Eriksdotter</b> MD, PhD, Professor at Kl	<ul> <li>Professor in Geriatrics and Aging at Karolinska Institute (KI) since 2010</li> <li>Education: MD, PhD from Karolinska</li> <li>Research focus on treatment &amp; care of dementia with focus on Alzheimer's</li> </ul>	Karolinska Moore Karolinska Institutet
<b>Johan Sandin</b> CSO Ph.D.	<ul> <li>Expert in in vivo Pharmacology with 16 years experience from the drug discovery industry within Neurology</li> <li>Education: Ph.D. in Neuropharmacology, Karolinska Institute</li> </ul>	Karolinska Institutet AstraZeneca
<b>Pontus Forsell</b> Head of Discovery & Research, Ph.D.	<ul> <li>Expert in drug screening with +20 years of experience from industrial research and drug development within CNS and Pain</li> <li>Education: Ph.D. in Medical Biochemistry &amp; Biophysics from Karolinska Institute</li> </ul>	AstraZeneca Orexo MERCK FROSST Karolinska Institutet
<b>Martin Jönsson</b> CEO	<ul> <li>Extensive experience in various senior management positions with &gt;20 years of international experience in the industry</li> <li>Education: MSc in BA from Lund University, Ottawa, Canada &amp; Freiburg, Germany</li> </ul>	Roche UNTERTET VARIANCEUTICALS

